LACTOLOGY FOUNDATION

Attapulgite combinations (ATC A07BC54) are oral antidiarrheal products that combine attapulgite with other intestinal adsorbents or excipients, providing local adsorptive and mucosa‑protective actions in the gut, with negligible systemic absorption and generally low direct risk in breastfeeding, while overall safety depends on the co‑components.atcddd.fhi+2

ATC A07BC54 overview

ATC code A07BC54 designates “attapulgite, combinations” within the subgroup A07BC “Other intestinal adsorbents,” part of the intestinal adsorbents class A07B among antidiarrheals. According to ATC rules, combinations that include intestinal antiinfectives are classified instead in A07A, so A07BC54 covers combinations where attapulgite is combined with other non‑antiinfective adsorbents or excipients.atcddd.fhi+3

Composition and examples

A07BC54 products typically contain attapulgite (magnesium aluminium phyllosilicate clay) together with other agents such as pectin‑type fibers, antacids, or formulation excipients designed to improve palatability and stability. Some legacy formulations also combined attapulgite with non‑absorbed antibacterial agents such as nifuroxazide; these would generally be classified in A07A when the antiinfective is considered a primary component.drugs.ncats+4

Pharmacology and mechanism

The therapeutic effect of A07BC54 combinations is dominated by attapulgite’s adsorptive capacity: it binds acids, bacteria, and toxins in the intestinal lumen and reduces water loss, thereby firming stools and relieving cramping. Co‑components (for example pectin or other fibers) add demulcent and gel‑forming properties, further coating the mucosa and enhancing local protection without introducing significant systemic activity.sciencedirect+5

Therapeutic indications

Attapulgite‑containing combinations are indicated for short‑term symptomatic treatment of acute, non‑specific diarrhea, including travellers’ diarrhea, in adults and older children. They are intended as adjuncts to oral rehydration therapy, not as substitutes for fluid and electrolyte replacement or for etiologic evaluation when red‑flag signs (fever, blood in stool, severe dehydration) are present.drugs+4

Pharmacokinetics relevant to lactation

Attapulgite is a non‑absorbed intestinal adsorbent: it acts locally in the gut and is eliminated unchanged in feces, with no meaningful systemic bioavailability. Non‑adsorbent excipients in these combinations (for example sweeteners, flavors, thickening agents) are used in standard oral doses and do not materially change the systemic exposure profile of the product from a lactation perspective.drugbank+3

Maternal safety and adverse effects

At recommended doses, attapulgite combinations are generally well tolerated; constipation is the most common adverse effect, with possible bloating, flatulence, stomach upset, or nausea. As with single‑ingredient attapulgite, these combinations should be avoided in patients with suspected bowel obstruction or severe chronic constipation, and they may reduce the absorption of concomitant oral medications if taken at the same time.sciencedirect+2

Lactation safety assessment

Because attapulgite is not absorbed, reference sources state that its presence in breast milk is unlikely and that its use is generally accepted as safe during breastfeeding. Consequently, the main toxico‑lactological determinant for A07BC54 products is the safety of any co‑components (for example antiinfectives, salicylates, or other systemically active agents), which should each be assessed individually in lactation resources before use.drugs+4

Potential effects on the breastfed infant

Direct exposure of the infant to attapulgite via breast milk is expected to be extremely low, and attapulgite‑related toxicity in the infant is not anticipated. Potential risks for the infant arise instead from systemically active co‑ingredients (where present) or from the underlying maternal diarrhea (risk of infectious transmission), so infant monitoring should focus on signs of infection, dehydration, or adverse effects consistent with the co‑medications rather than the clay itself.drugs+5

Practical recommendations in breastfeeding

For breastfeeding women with mild acute diarrhea, first‑line management remains oral rehydration, hygiene measures, and, when needed, antidiarrheals such as loperamide, which has well‑documented compatibility with lactation. If an attapulgite combination is considered, clinicians should select products that contain only non‑absorbed adsorbents without systemic antiinfectives or salicylates, use the lowest effective dose for the shortest duration, separate dosing from other oral medicines, and document both maternal response and infant monitoring.infantrisk+5

Role among intestinal adsorbents

Compared with single‑ingredient attapulgite (A07BC04), A07BC54 combinations offer similar local adsorptive benefits but add formulation complexity and potential additional active substances, which can affect lactation risk. When products are purely adsorbent combinations, their overall risk–benefit balance in breastfeeding is favorable; however, when safer, well‑characterized single agents (for example loperamide or simple kaolin/pectin) are sufficient, they are usually preferred as first‑line therapy in lactating women.drugbank+5